Glenmark Wins U.S. FDA Nod and 180-Day Exclusivity for Generic FloVent Inhaler

An update from Glenmark Pharmaceuticals Limited ( (IN:GLENMARK) ) is now available.

Glenmark Specialty SA, a unit of Glenmark Pharmaceuticals, has received final U.S. FDA approval for its Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, deemed bioequivalent and therapeutically equivalent to GlaxoSmithKline’s FloVent HFA. The product will be distributed in the U.S. from March 2026, reinforcing Glenmark’s position in respiratory treatments.

The FDA has granted the product Competitive Generic Therapy status, making Glenmark the first approved applicant and eligible for 180 days of market exclusivity upon commercialization. This exclusivity gives Glenmark a valuable advantage in a FloVent HFA 44 mcg market that generated about $520.1 million in U.S. sales over the 12 months to January 2026, potentially boosting revenue while supporting wider access to lower-cost inhalation therapies.

Company executives said the approval underscores Glenmark’s technical capabilities in complex inhalation generics and aligns with its strategy to grow its U.S. respiratory portfolio. The launch is expected to enhance Glenmark’s competitive standing in the U.S. generics market and offer physicians and patients an additional option for affordable respiratory care.

More about Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is an India-headquartered global pharmaceutical company with a significant presence in specialty and generics markets, including the U.S. It focuses on respiratory therapies and other complex formulations, marketing products through its subsidiary Glenmark Pharmaceuticals Inc., USA to expand access to affordable medicines.

Average Trading Volume: 15,241

Technical Sentiment Signal: Buy

Current Market Cap: 599.3B INR

See more data about GLENMARK stock on TipRanks’ Stock Analysis page.